OMass Therapeutics is a privately-held biotechnology company, based in Oxford, UK. The Company is focused on structural mass spectrometry to discover novel medicines. It uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies.

OMass is an Oxford University spin-out company applying MS technology to drug discovery.

The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulation of complex formation, with both effects, binding and function, being measured by a change in mass.

These methods are being applied to drug discovery for a variety of complex targets, including membrane receptors.

Developing

Company Details

CEO:

Jonathan Hopper

CSO:

Ali Jazayeri

Syncona Representatives:

Martin Murphy